Thermo Fisher Scientific to Showcase Global Innovation at DCAT Week 2022

Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers

WALTHAM, Mass.--(BUSINESS WIRE)--This week at the Drug, Chemical & Associated Technologies Association (DCAT) conference in New York, NY, Thermo Fisher Scientific will highlight its investments and innovation across its global pharma services network from development to commercial.

“We continue to invest strategically in both global capacity and advanced capabilities that simplify the supply chain and accelerate the pace of pharmaceutical development,” said Leon Wyszkowski, president of commercial operations, pharma services, Thermo Fisher Scientific. “Our focus has been on developing integrated capabilities that connect the entire value chain — from early development and scale-up to commercial manufacturing — as well as leveraging new transformative digital technologies to help speed the delivery of breakthrough medicines and therapies to patients.”

Simplifying the Supply Chain for Cell and Gene Therapies
The demand for cell and gene therapies is fueling exponential growth. This year, Thermo Fisher will open one of the largest viral vector sites in North America. The nearly 300,000-square-foot facility in Plainville, Mass., will extend the company’s global commercial viral vector network to six sites.

Later this year, Thermo Fisher will expand its cell therapy network with the addition of a new cell therapy development and cGMP manufacturing center at the University of California San Francisco, Mission Bay campus. The site will provide customers with integrated solutions to reduce cost and accelerate adoption of cell therapies.

To address the need for commercial-quality plasmid DNA, Thermo Fisher opened its new cGMP Plasmid manufacturing facility in Carlsbad, Calif., to support clinical and commercial needs for high quality raw material and drug substance development for cell and gene therapies and vaccines.

Additionally, the company is also launching new mRNA synthesis capabilities to produce drug substance for vaccines and therapies

Enabling Early-Stage Process Development
Thermo Fisher has added new capabilities to support early-stage development, shorten pre-clinical study timelines and accelerate commercialization. New translational sciences labs will open in San Diego, Calif., and Alachua, Fla., to support cell and gene therapy development for the pharmaceutical innovators transitioning drug candidates into pre-clinical studies.

In addition, new Quick to Clinic integrated services connect services across the value chain and create workflows to allow rapid process development and reduced cycle times. New Quick to Care for advanced therapies offers an end-to-end, customizable solution that integrates drug development and clinical services across the cell and gene therapy value chain to speed access to breakthrough therapies. New Patheon Commercial Packaging Services for Cell and Gene Therapies combine GMP storage, serialization, ultracold and cryogenic packaging, and global distribution to meet specialized needs to ensure CGT supply chain integrity.

Expanding Steriles, Product Development & Biologics Capabilities
The company has expanded its capabilities to support the accelerated demand for global steriles and biologics manufacturing. Over the last two years, Thermo Fisher has added 13 new aseptic filling lines and expanded its product development services across its global network.

Thermo Fisher is doubling biologics manufacturing capacity at its St. Louis, Mo., site to support production growth from 2KL to 5KL. In addition, the company assumed operational responsibility of its new state-of-the-art biologics manufacturing facility in Lengnau, Switzerland, which features highly flexible bioproduction technologies and provides a pathway from development to large-scale production.

Later this year, the company will expand into Asia-Pacific. In Hangzhou, China, a new manufacturing facility will be the first to offer integrated biologics drug substance and sterile drug product capabilities. In Singapore, a new sterile manufacturing facility will offer large-scale capacity and high-speed filling.

Digital Transformation of the Supply Chain
Thermo Fisher is leveraging new digital technologies across its pharma services network to create manufacturing efficiencies and streamlined processes. New capabilities include implementation of Pharma 4.0 to harmonize and integrate data and drive digital transformation within all phases of drug development and manufacturing. In addition, the company’s new mysupply digital supply chain platform provides customers with visibility and collaboration across their full product lifecycle including daily order management, batch tracking and monthly forecasting.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.